Crazy!!! Thanks to Max who recommended me waltersalerts you can google it, I made 160% on their last pick!! If your not subscribed with waltersalerts your missing out!
Sentiment: Strong Sell
I would agree that OPK is an attractive company with an interesting pipeline, but I would think that Dr. Frost's connection with TEVA would make that company a more logical buyer.
Over fifty percent of the American citizens see Obama different than what you erringly describe. Get your facts straight. Leave politics to those that are abreast of what is going on. Just count yourself lucky we don't have a leader like Robert Mugabe of Rhodesia. Spend more time counting your blessings rather than spewing brown sugar. Why you lie so much is baffling.
Bosutinib is a dud, commercially. So getting Iclusig would ensure that the huge PFE investment in commercializing Bos does not go to waste: sales force, training, strategy on CML, ETC.
Not to mention the ARIAD super fast discovery and development capabilities as well as other drugs, like 113 for NSCLC.
I agree, once FDA ends hold on Iclusig it will take over for all 2nd line drugs and eventually first line. Then..all of the other potential cancers, like GIST that PFE would be able to fund and to add to that the apparently best in class ALK inhibitor, AP26113 plus the rapid discovery technology that ARIAD. Would bring to the table.
Santa says the December 2013 Consensus is Obama is Unqualified, Incompetent, Egomaniac, Marxist, Big Liar and Narcissist.
The Obamacare Crisis --- Be ready now you know.
Good article on falsely sold Obamacare from of all sources the NYT!
Contributing Op-Ed Writer
The Obamacare Crisis
By THOMAS B. EDSALL
Published: November 19, 2013
The piece ends:
There is obvious irony in the possibility that technology could bring down the most high-tech president in American history. Is the federal government equipped to take responsibility for a venture of such magnitude and importance?
Technology aside, the stakes could not be higher for the Democratic Party.
The Affordable Care Act “is often compared to Social Security and Medicare but these comparisons are imprecise and misleading,” as Edward Carmines, a political scientist at Indiana University, put it in an email: “The distinctive feature of the new health care law is it redistributive nature which is mostly absent from Social Security and Medicare.”
Carmines went on, succinctly analyzing the political problem lying at the heart of Obamacare:
“Most of the benefits of the new program will go to the poor and less-well-off and most of the costs will be born by the well off. Neither is true of Medicare or Social Security. When the new law was passed it was hailed by the New York Times as the most redistributive policy in a generation, and they were right. It was not sold as being markedly redistributive, of course, but that is how it was designed and will operate. This does not mean it is a bad policy or doomed to fail. But it does mean that it was bound to be caught up in controversy and heated debate.”